No Clinically Significant Interaction Between GLP-1 Receptor Agonists and Mirena IUD
GLP-1 receptor agonists do not interact with the levonorgestrel-releasing intrauterine device (Mirena IUD) and can be used safely together without compromising contraceptive efficacy.
Key Evidence
The Mirena IUD delivers levonorgestrel locally to the uterus, bypassing first-pass metabolism and oral absorption pathways entirely. This fundamental difference in drug delivery eliminates the theoretical concern about GLP-1 RA-induced delayed gastric emptying affecting contraceptive absorption—a concern that only applies to oral contraceptives 1, 2.
Direct Pharmacokinetic Studies
High-quality drug interaction studies demonstrate that:
Semaglutide (oral formulation) does not reduce the bioavailability of levonorgestrel when given as an oral contraceptive. The AUC ratio was 1.06 (90% CI: 0.97-1.17), well within the no-effect criterion of 0.80-1.25 1
A separate study confirmed semaglutide did not reduce levonorgestrel bioavailability, though it showed a 20% increase in levonorgestrel AUC (1.20 [1.15-1.26])—an increase that is not clinically concerning and does not reduce contraceptive efficacy 2
The Cmax (peak concentration) of levonorgestrel remained unaffected by GLP-1 RA co-administration 1, 2
Why the Mirena IUD Is Even Safer
While these studies examined oral levonorgestrel, the Mirena IUD provides an even more favorable scenario because:
- Local delivery: Levonorgestrel is released directly into the uterine cavity, achieving high local concentrations with minimal systemic absorption
- No gastric involvement: The IUD completely bypasses the gastrointestinal tract, making GLP-1 RA effects on gastric emptying irrelevant
- Steady-state release: The IUD provides continuous hormone release independent of any oral drug absorption dynamics
Clinical Implications
You can confidently prescribe GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide) to patients using Mirena IUDs without any special precautions or concerns about contraceptive failure.
Important Context from Recent Literature
Recent evidence suggests that combining GLP-1 RAs with levonorgestrel-releasing IUDs may actually be preferred in obese women because oral progestin bioavailability is reduced in obesity, whereas IUD delivery maintains efficacy 3. This combination has been associated with reduced endometrial cancer risk in high-risk women 3.
Common Pitfall to Avoid
Do not confuse this situation with oral contraceptives. While GLP-1 RAs may theoretically affect oral contraceptive absorption due to delayed gastric emptying 4, this concern does not apply to IUDs, implants, patches, or injections—all of which bypass the GI tract entirely.
Bottom Line
The Mirena IUD and GLP-1 receptor agonists have no pharmacokinetic or pharmacodynamic interaction. Contraceptive efficacy remains fully intact, and no additional contraceptive precautions are needed when starting or continuing GLP-1 RA therapy in patients with Mirena IUDs.